In-depth cooperation for win-win progress

On June 28, 2021, Kexing Biopharmaceutical Co., Ltd. and Taizhou Mabtech Pharmaceutical Co., Ltd. (hereinafter referred to as Taizhou Mabtech) signed the CMAB008 International Exclusive Commercial License Agreement. The signing of the agreement was immediately followed by the two sides’ close coordination in the registration of infliximab in 32 countries for overseas commercial cooperation, making significant progress. Both sides are now ready for in-depth cooperation after several rounds of communication and negotiation.

Kexing Biopharm granted the exclusive promotion right of infliximab (Reminton®)
On March 31, 2022, Kexing Biopharmaceutical Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that the Exclusive Promotion Service Agreement for Infliximab (Reminton®) in Chinese Mainland was signed with Taizhou Mabtech, granting Kexing Biopharm the exclusive promotion right of infliximab (Reminton®) in Chinese mainland.

There is a large, long-term unmet need for infliximab as it currently targets more than 10 million people in China, a number that continues to grow. In view of this and with the exclusive promotion right of the drug in the Chinese mainland, we will be able to enrich our product lines and expand the scope of cooperation in the field of autoimmunity. This development is expected to enhance our influence, competitiveness and future business performance.